Evidence map›Paper›PMID 39460829›Full record

ArticleMolecular genetics and genomics : MGG2024

Differential cellular communication in tumor immune microenvironment during early and advanced stages of lung adenocarcinoma.

Mudita Shukla, Ram Rup Sarkar

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular genetics and genomics : MGG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Experimental and therapeutic medicine · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mudita ShuklaChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India.
Ram Rup SarkarChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India. rr.sarkar@ncl.res.in.ORCID http://orcid.org/0000-0001-7115-163X

Funding

Department of Biotechnology, Ministry of Science and Technology, India BT/PR40128/BTIS/137/43/2022Department of Science and Technology, Ministry of Science and Technology, India DST-WOSA (LS-154/2019)
6 · The paper itself

Abstract

Heterogeneous behavior of each cell type and their cross-talks in tumor immune microenvironment (TIME) refers to tumor immunological heterogeneity that emerges during tumor progression and represents formidable challenges for effective anti-tumor immune response and promotes drug resistance. To comprehensively elucidate the heterogeneous behavior of individual cell types and their interactions across different stages of tumor development at system level, a computational framework was devised that integrates cell specific data from single-cell RNASeq into networks illustrating interactions among signaling and metabolic response genes within and between cells in TIME. This study identified stage specific novel markers which remodel the cross-talks, thereby facilitating immune stimulation. Particularly, multicellular knockout of metabolic gene APOE (Apolipoprotein E in mast cell, myeloid cell and fibroblast) combined with signaling gene CAV1 (Caveolin1 in endothelial and epithelial cells) resulted in the activation of T-cell mediated signaling pathways. Additionally, this knockout also initiated intervention of cytotoxic gene regulations during tumor immune cell interactions at the early stage of Lung Adenocarcinoma (LUAD). Furthermore, a unique interaction motif from multiple cells emerged significant in regulating the overall immune response at the advanced stage of LUAD. Most significantly, FCER1G (Fc Fragment of IgE Receptor Ig) was identified as the common regulator in activating the anti-tumor immune response at both stages. Predicted markers exhibited significant association with patient overall survival in patient specific dataset. This study uncovers the significance of signaling and metabolic interplay within TIME and discovers important targets to enhance anti-tumor immune response at each stage of tumor development.

Indexed as

Adenocarcinoma of LungCell CommunicationLung NeoplasmsTumor MicroenvironmentApolipoproteins EBiomarkers, TumorCaveolin 1Gene Expression Regulation, NeoplasticHumansMast CellsNeoplasm StagingSignal TransductionApoE protein, humanApolipoproteins EBiomarkers, TumorCAV1 protein, humanCaveolin 1Early and advanced stages of Lung AdenocarcinomaImmunomodulationMulticellular communicationSignaling-metabolic cross-talksTumor immune microenvironmentTumor immunological heterogeneity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.